Bayer subsidiary Vividion secures rights to Werner helicase inhibitor
Bayer subsidiary Vividion Therapeutics has secured exclusive worldwide rights to develop and commercialise VVD-214, the Werner helicase (WRN) covalent inhibitor, enhancing its oncology pipeline.
Roche and Vividion discovered and developed VVD-214 through a global partnership and licence agreement.
In 2020, the companies agreed to discover and develop small molecules for a range of therapeutic targets.
The acquisition of VVD-214 rights by Vividion complements its portfolio of investigational therapeutics aimed at treating cancers and immune disorders.
Preliminary data from a Phase I trial indicated that the therapy is well-tolerated and exhibits signs of activity.
The trial is assessing VVD-214 as a single agent and in conjunction with pembrolizumab for those with various solid tumours showing microsatellite instability (MSI), such as endometrial, colorectal, gastric and ovarian cancers.
WRN is a deoxyribonucleic acid (DNA) repair enzyme and a synthetic lethal target for cancers with MSI.
VVD-214's mechanism aims to induce lethal DNA damage in these cancers while sparing healthy cells.
This approach could offer a new treatment avenue for patients with limited options, particularly those who relapse or become refractory to immune checkpoint inhibitors.
Vividion Therapeutics CEO Aleksandra Rizo stated: 'Bringing VVD-214, the only clinical-stage covalent inhibitor of WRN in development worldwide, into our portfolio marks an incredibly exciting moment for Vividion.
'We are eager to progress development of this compound, building on the encouraging clinical data we've seen to date, as part of our mission to transform treatment for patients with cancer and other serious diseases.'
Vividion has Phase I trials for other potential oral cancer therapies, including a Kelch-like ECH-associated protein 1 (KEAP1) activator, a RAS-phosphatidylinositol 3-kinase alpha (PI3Kα) inhibitor and a signal transducer and activator of transcription 3 (STAT3) inhibitor.
The company is progressing the discovery of several drug programmes towards the clinic and has a pipeline of early discovery opportunities in immunology and oncology, utilising its chemoproteomics platform.
"Bayer subsidiary Vividion secures rights to Werner helicase inhibitor" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Goldman Sachs Upgrades Bayer (BAYRY) to Buy
On Thursday, Goldman Sachs analyst James Quigley upgraded Bayer Aktiengesellschaft (OTC:BAYRY) to Buy from Neutral, while setting a price target of EUR 33. Quigley indicated that the stock's risk/reward profile appears positive as it approaches H2 2025, with potential catalysts that could drive a re-rating in the medium term. A closeup of pills in a pharmacy, representing the high quality medications of the company. This upgrade follows Bayer's strong operational start to the year, characterized by cost discipline in its Crop Science division and robust momentum in its underlying Pharmaceuticals business. Goldman Sachs suggests that these factors indicate Bayer may have reached the bottom of its negative earnings revision cycle. In key business developments, Bayer's EPS stood at EUR 2.49 in Q1 2025, keeping the company on track to achieve EUR 4.50 to 5.00 at constant currencies for the full year. While sales in the company's Crop Science division declined by 3% due to regulatory impacts affecting higher-margin sales, the Pharmaceuticals segment sales grew by 4% due to an 80% year-over-year increase in Nubeqa and Kerendia sales. Nubeqa is a prostate cancer drug, while Kerendia is used to treat chronic kidney disease associated with type 2 diabetes. The Consumer Health segment sales also increased by 2.5%. Bayer Aktiengesellschaft (OTC:BAYRY) is a global life science company. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. While we acknowledge the potential of BAYRY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Related Content OTC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
We always joked dad looked nothing like his parents - then we found out why
Matthew's dad had brown eyes and black hair. His grandparents had piercing blue eyes. There was a running joke in his family that "dad looked nothing like his parents", the teacher from southern England says. It turned out there was a very good reason for this. Matthew's father had been swapped at birth in hospital nearly 80 years ago. He died late last year before learning the truth of his family history. Matthew - not his real name - contacted the BBC after we reported on the case of Susan, who received compensation from an NHS trust after a home DNA test revealed she had been accidentally switched for another baby in the 1950s. BBC News is now aware of five cases of babies swapped by mistake in maternity wards from the late 1940s to the 1960s. Lawyers say they expect more people to come forward driven by the increase in cheap genetic testing. During the pandemic, Matthew started looking for answers to niggling questions about his family history. He sent off a saliva sample in the post to be analysed. The genealogy company entered his record into its vast online database, allowing him to view other users whose DNA closely matched his own. "Half of the names I'd just never heard of," he says. "I thought, 'That's weird', and called my wife to tell her the old family joke might be true after all." Matthew then asked his dad to submit his own DNA sample, which confirmed he was even more closely related to the same group of mysterious family members. Matthew started exchanging messages with two women who the site suggested were his father's cousins. All were confused about how they could possibly be related. Working together, they eventually tracked down birth records from 1946, months after the end of World War Two. The documents showed that one day after his father was apparently born, another baby boy had been registered at the same hospital in east London. That boy had the same relatively unusual surname that appeared on the mystery branch of the family tree, a link later confirmed by birth certificates obtained by Matthew. It was a lightbulb moment. "I realised straight away what must have happened," he says. "The only explanation that made sense was that both babies got muddled up in hospital." Matthew and the two women managed to construct a brand new family tree based on all of his DNA matches. "I love a puzzle and I love understanding the past," he says. "I'm quite obsessive anyway, so I got into trying to reverse engineer what had happened." Before World War Two, most babies in the UK were born at home, or in nursing homes, attended by midwives and the family doctor. That started to change as the country prepared for the launch of the NHS in 1948, and very gradually, more babies were delivered in hospital, where newborns were typically removed for periods to be cared for in nurseries. "The baby would be taken away between feeds so that the mother could rest, and the baby could be watched by either a nursery nurse or midwife," says Terri Coates, a retired lecturer in midwifery, and former clinical adviser on BBC series Call The Midwife. "It may sound paternalistic, but midwives believed they were looking after mums and babies incredibly well." It was common for new mothers to be kept in hospital for between five and seven days, far longer than today. To identify newborns in the nursery, a card would be tied to the end of the cot with the baby's name, mother's name, the date and time of birth, and the baby's weight. "Where cots rather than babies were labelled, accidents could easily happen", says Ms Coates, who trained as a nurse herself in the 1970s and a midwife in 1981. "If there were two or more members of staff in the nursery feeding babies, for example, a baby could easily be put down in the wrong cot." By 1956, hospital births were becoming more common, and midwifery textbooks were recommending that a "wrist name-tape" or "string of lettered china beads" should be attached directly to the newborn. A decade later, by the mid-1960s, it was rare for babies to be removed from the delivery room without being individually labelled. Stories of babies being accidentally switched in hospital were very rare at the time, though more are now coming to light thanks to the boom in genetic testing and ancestry websites. The day after Jan Daly was born at a hospital in north London in 1951, her mother immediately complained that the baby she had been given was not hers. "She was really stressed and crying, but the nurses assured her she was wrong and the doctor was called in to try to calm her," Jan says. The staff only backed down when her mum told them she'd had a fast, unassisted delivery, and pointed out the clear forceps marks on the baby's head "I feel for the other mother who had been happily feeding me for two days and then had to give up one baby for another," she says. "There was never any apology, it was just 'one of those silly errors', but the trauma affected my mother for a long time." Matthew's father, an insurance agent from the Home Counties, was a keen amateur cyclist who spent his life following the local racing scene. He lived alone in retirement and over the last decade his health had been deteriorating. Matthew thought long and hard about telling him the truth about his family history but, in the end, decided against it. "I just felt my dad doesn't need this," he says. "He had lived 78 years in a type of ignorance, so it didn't feel right to share it with him." Matthew's father died last year without ever knowing he'd been celebrating his birthday a day early for the past eight decades. Since then, Matthew has driven to the West Country to meet his dad's genetic first cousin and her daughter for coffee. They all got on well, he says, sharing old photos and "filling in missing bits of family history". But Matthew has decided not to contact the man his father must have been swapped with as a baby, or his children – in part because they have not taken DNA tests themselves. "If you do a test by sending your saliva off, then there's an implicit understanding that you might find something that's a bit of a surprise," Matthew says. "Whereas with people who haven't, I'm still not sure if it's the right thing to reach out to them - I just don't think it's right to drop that bombshell." Woman contacted by stranger on DNA site - and the truth about her birth unravelled Swapped at birth: How two women discovered they weren't who they thought they were Canadians switched at birth get an apology 70 years on
Yahoo
a day ago
- Yahoo
Bayer subsidiary Vividion secures rights to Werner helicase inhibitor
Bayer subsidiary Vividion Therapeutics has secured exclusive worldwide rights to develop and commercialise VVD-214, the Werner helicase (WRN) covalent inhibitor, enhancing its oncology pipeline. Roche and Vividion discovered and developed VVD-214 through a global partnership and licence agreement. In 2020, the companies agreed to discover and develop small molecules for a range of therapeutic targets. The acquisition of VVD-214 rights by Vividion complements its portfolio of investigational therapeutics aimed at treating cancers and immune disorders. Preliminary data from a Phase I trial indicated that the therapy is well-tolerated and exhibits signs of activity. The trial is assessing VVD-214 as a single agent and in conjunction with pembrolizumab for those with various solid tumours showing microsatellite instability (MSI), such as endometrial, colorectal, gastric and ovarian cancers. WRN is a deoxyribonucleic acid (DNA) repair enzyme and a synthetic lethal target for cancers with MSI. VVD-214's mechanism aims to induce lethal DNA damage in these cancers while sparing healthy cells. This approach could offer a new treatment avenue for patients with limited options, particularly those who relapse or become refractory to immune checkpoint inhibitors. Vividion Therapeutics CEO Aleksandra Rizo stated: 'Bringing VVD-214, the only clinical-stage covalent inhibitor of WRN in development worldwide, into our portfolio marks an incredibly exciting moment for Vividion. 'We are eager to progress development of this compound, building on the encouraging clinical data we've seen to date, as part of our mission to transform treatment for patients with cancer and other serious diseases.' Vividion has Phase I trials for other potential oral cancer therapies, including a Kelch-like ECH-associated protein 1 (KEAP1) activator, a RAS-phosphatidylinositol 3-kinase alpha (PI3Kα) inhibitor and a signal transducer and activator of transcription 3 (STAT3) inhibitor. The company is progressing the discovery of several drug programmes towards the clinic and has a pipeline of early discovery opportunities in immunology and oncology, utilising its chemoproteomics platform. "Bayer subsidiary Vividion secures rights to Werner helicase inhibitor" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
